Breaks Categories: News

MondayJul 28, 2025 11:00 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Joins Exclusive Serie B Multi-Club Ownership Ranks, Juve Stabia Valuation Surges 245%

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company pursuing a multi-club ownership (MCO) strategy, has become the second MCO in Italy’s Serie B League alongside City Football Group, majority owned by Abu Dhabi United Group. Brera owns SS Juve Stabia, while City Group holds Palermo FC and Manchester City FC. Executive Chairman Daniel J. McClory said the Serie B owners’ meetings in Rome highlighted Brera’s integration into the league’s top ownership group. Juve Stabia, dubbed “The Second Team of Naples,” posted the highest market value increase in Serie B over the 2024-25 season, rising 245% to US$32 million from…

Continue Reading

MondayJul 28, 2025 10:58 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces 1-for-12 Reverse Stock Split Effective August 5

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery platforms, will implement a 1-for-12 reverse stock split of its common stock effective August 5, 2025. Shares will begin trading on a split-adjusted basis on the NYSE American under the existing ticker “CLDI,” with a new CUSIP of 320703 408. The reverse split, approved by shareholders on July 9 and ratified by the board on July 11, is intended to optimize market dynamics, expand investor appeal and align trading conditions with shareholder interests. Every 12 pre-split shares will convert into one post-split share, with fractional shares…

Continue Reading

MondayJul 28, 2025 10:45 am

NetworkNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) to Host July 28 Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Fifty 1 Labs (OTC: FITY), a leader in AI-powered health and wellness solutions, announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event, streamed live on X (formerly Twitter), will feature Senior Scientist Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders). The teleconference will highlight the company’s strategic roadmap for subsidiary Fifty 1 AI Labs, including AI-driven drug repurposing for functional medicine, a $1 million R&D investment, and plans for a $5–10 million biotech acquisition by 2027. Management underscored alignment…

Continue Reading

MondayJul 28, 2025 10:34 am

NetworkNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Enterprise Healthcare Solutions Website and Upgrades Provider Directory

HealthLynked (OTCQB: HLYK), a pioneer in healthcare technology and patient engagement, announced the launch of its newly designed Enterprise Healthcare Solutions Website, www.hlykgroup.com, and significant enhancements to its national provider directory. The new platform serves as a centralized hub for insurance carriers, pharmaceutical companies, marketing firms, ACOs, healthcare networks, and large employers, offering tools for patient engagement, population health, clinical research, coordinated care, and cost management. Upgrades to the consumer-facing provider directory include faster performance and localized provider suggestions, giving patients improved flexibility and transparency in selecting care. CEO Dr. Michael Dent said the developments reflect HealthLynked’s expanding role in…

Continue Reading

MondayJul 28, 2025 9:45 am

NetworkNewsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Completes Name and Ticker Change from Mullen Automotive

Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced that its previously disclosed name change from Mullen Automotive Inc. to Bollinger Innovations, Inc. is effective as of July 28, 2025, along with its new Nasdaq stock symbol “BINI.” The company stated the transition unifies its commercial Class 1, 3 and 4 vehicles under a single brand identity. CEO and Chairman David Michery said the move marks the completion of the company’s brand evolution while having no impact on its legal structure or operations. No shareholder action is required as a result of the changes. To view the full press release,…

Continue Reading

MondayJul 28, 2025 9:00 am

NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder and former CEO of Oncoceutics Inc., brings over 20 years of experience in biotechnology leadership and financial markets, with a track record in developing targeted therapies for solid tumors, including HK327M-mutant gliomas. Oncoceutics was acquired by Chimerix Inc. (NASDAQ: CMRX) for $450 million in 2021 and later by Jazz Pharmaceuticals for $935 million in April 2025. Lantern CEO Panna Sharma said Dr. Schalop’s expertise in…

Continue Reading

FridayJul 25, 2025 3:38 pm

NetworkNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Poised for Steady Production, Long-Term Success in British Columbia 

Amid the rising value of precious metals, Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) began processing high-grade gold and silver ore at its Merritt Mill facility, highlighting a key step forward in its growth. “Nicola expects to cumulatively process 60,000 (tn) of ore and produce 21,000 (oz) of gold-equivalent concentrate at full production capacity annual rate. The Merritt Mill provides accessible, reliable revenue to not only its British Columbian partners, but it also sustains its own copper, gold and silver projects across the province,” reads a recent article. “We are excited to realize that Nicola is morphing into a steady and…

Continue Reading

FridayJul 25, 2025 3:29 pm

NetworkNewsBreaks – Ucore Rare Metals Inc.’s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Core to Blueprint to Secure Rare Earth Independence

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioned as a key player in a strategy to build a secure, independent rare earth supply chain in North America. Triggered by China’s export restrictions on key elements, a potential blueprint includes diversifying rare earth sources, using modular refining with Ucore’s RapidSX(TM) technology, anchoring refining with magnet-making hubs, establishing stockpiles and off-take agreements, and proving the chain with traceability and ESG standards. Ucore’s RapidSX(TM) is central to reducing bottlenecks in chemical separation, helping to develop a resilient, transparent, and strategically independent supply chain.  To view the full article, visit https://nnw.fm/FFmqw About Ucore…

Continue Reading

FridayJul 25, 2025 3:18 pm

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB): Innovation Meets Science Through Scalable Platform  

Nutriband (NASDAQ: NTRB) is positioning at the forefront of abuse-deterrent drug delivery in advancing its flagship fentanyl patch and buprenorphine candidates. The company combines transdermal innovation with abuse-deterrent science to meet critical public health needs. According to Nurtiband, AVERSA Fentanyl, with the possibility to reach peak annual U.S. sales of $80 to $200 million, holds the potential to be the world’s first opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. In addition, Nutriband is advancing AVERSA Buprenorphine, which upon approval is projected to achieve peak U.S. sales between…

Continue Reading

FridayJul 25, 2025 3:10 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients

Clene (NASDAQ: CLNN), together with its subsidiary Clene Nanomedicine Inc., is preparing to initiate neurofilament biomarker analyses for its lead drug candidate CNM-Au8(R) in ALS, following feedback from the FDA during a recent Type C meeting. Slated for early Q4 2025, the analyses will assess changes in neurofilament light chain (“NfL”)—a recognized marker for neurodegeneration—among nearly 200 patients treated through the Expanded Access Program for CNM-Au8. “We are encouraged by the FDA’s collaborative approach and their constructive feedback on our NfL biomarker analysis plan from the ongoing NIH-sponsored EAP program,” said Benjamin Greenberg, MD, Head of Medical at Clene. “With…

Continue Reading